354 related articles for article (PubMed ID: 26035328)
1. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
2. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir: successful experience in a challenging patient.
Bonadies G; Maraolo AE; Tambaro O; Palmiero G; Di Filippo G; Orlando R
AIDS; 2015 Jun; 29(10):1269-71. PubMed ID: 26035327
[No Abstract] [Full Text] [Related]
4. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
[TBL] [Abstract][Full Text] [Related]
5. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir-based regimens are effective in HIV-1 group O-infected patients.
Depatureaux A; Leoz M; Le Moal G; Pathé JP; Pavie J; Batisse D; Daneluzzi V; Genet P; Gerard L; Lascaux-Cametz AS; Lambolez T; Chennebault JM; Plantier JC
J Acquir Immune Defic Syndr; 2012 Sep; 61(1):e1-3. PubMed ID: 22918125
[No Abstract] [Full Text] [Related]
8. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
[TBL] [Abstract][Full Text] [Related]
9. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Charpentier C; Lee GQ; Rodriguez C; Visseaux B; Storto A; Fagard C; Molina JM; Katlama C; Yazdanpanah Y; Harrigan PR; Descamps D
J Antimicrob Chemother; 2015 Jul; 70(7):2090-6. PubMed ID: 25755001
[TBL] [Abstract][Full Text] [Related]
10. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
[TBL] [Abstract][Full Text] [Related]
11. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
12. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
[No Abstract] [Full Text] [Related]
13. Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.
Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Yeni P; Strohmaier KM; Rodgers AJ; Barnard RJ; Nguyen BY; Teppler H;
Antivir Ther; 2015; 20(3):307-15. PubMed ID: 25350973
[TBL] [Abstract][Full Text] [Related]
14. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir and etravirine are active against HIV type 1 group O.
Briz V; Garrido C; Poveda E; Morello J; Barreiro P; de Mendoza C; Soriano V
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):225-7. PubMed ID: 19239363
[TBL] [Abstract][Full Text] [Related]
16. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
[TBL] [Abstract][Full Text] [Related]
17. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
[TBL] [Abstract][Full Text] [Related]
19. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
20. Performance of the Abbott RealTime HIV-1 viral load assay is not impacted by integrase inhibitor resistance-associated mutations.
Young TP; Cloherty G; Fransen S; Napolitano L; Swanson P; Herman C; Parkin NT; Hackett J
J Clin Microbiol; 2011 Apr; 49(4):1631-4. PubMed ID: 21289145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
